Mic1-3KO tachyzoite a live attenuated vaccine candidate against toxoplasmosis derived from a type I strain shows features of type II strain

Experimental Parasitology

Volumn 123, Issue 2, 2009, Pages 111-117

  Moiré, Nathalie ^a   Dion, Sarah ^a   Lebrun, Maryse ^b   Dubremetz, Jean François ^b   Dimier Poisson, Isabell ^a  

^a UNIVERSITÉ DE TOURS   (France)

^b INSTITUT DE GÉNOMIQUE FONCTIONNELLE   (France)

Author keywords

Apicomplexa; Attenuated strain; Brain cysts; Dissemination; Toxoplasma gondii; Virulence

Indexed keywords

CHEMOKINE; CYTOKINE; GAMMA INTERFERON; LIVE VACCINE; MONOCYTE CHEMOTACTIC PROTEIN 1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CONTROLLED STUDY; CYST; CYTOKINE RELEASE; FEMALE; HOST PARASITE INTERACTION; IN VIVO STUDY; MICROBIAL ATTENUATION; MOUSE; NONHUMAN; OUTBRED STRAIN; PARASITE VIRULENCE; PRIORITY JOURNAL; STRAIN DIFFERENCE; SURVIVAL; TACHYZOITE; TISSUE DISTRIBUTION; TISSUE LEVEL; TOXOPLASMA GONDII; TOXOPLASMOSIS; VACCINATION; WILD TYPE;

ANIMALS; BRAIN; CELL ADHESION MOLECULES; CHEMOKINES; CYTOKINES; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; FEMALE; MICE; MICE, INBRED CBA; PROTOZOAN PROTEINS; PROTOZOAN VACCINES; TOXOPLASMA; TOXOPLASMOSIS, ANIMAL; VACCINES, ATTENUATED; VIRULENCE;

APICOMPLEXA; MUS; TOXOPLASMA GONDII;

EID: 69249229580     PISSN: 00144894     EISSN: 10902449     Source Type: Journal    
DOI: 10.1016/j.exppara.2009.06.003     Document Type: Article

References (30)

1. Buxton D. Toxoplasmosis: the first commercial vaccine. Parasitology Today 9 (1993) 335-337
2. Cérède O., Dubremetz J.F., Soête M., Deslée D., Vial H., Bout D., and Lebrun M. Synergistic role of micronemal proteins in Toxoplasma gondii virulence. Journal of Experimental Medicine 201 (2005) 453-463
3. Dao A., Soête M., Sergent V., Deslée D., Fortier B., and Dubremetz J.F. Potential of β-galactosidase-expressing Toxoplasma gondii for in situ localization and observation of rare stages of the parasite life cycle. Parasitology Research 88 (2002) 69-72
4. Derouin F., and Garin Y.J.F. Toxoplasma gondii: blood and tissue kinetics during acute and chronic infection in mice. Experimental Parasitology 73 (1991) 460-468
5. Djurkovic-Djakovic O., Nikolic A., Bobic B., Klun I., and Aleksic A. Stage conversion of Toxoplasma gondii RH parasites in mice by treatment with atovaquone and pyrrolidine dithiocarbamate. Microbes and Infection 7 (2005) 49-54
6. Dzierszinski F., Mortuaire M., Cesbron-Delaw M.F., and Tomavo S. Targeted disruption of the glycosylphosphatidylinositol anchored surface antigen SAG3 gene in Toxoplasma gondii decreases cell adhesion and drastically reduces virulence in mice. Molecular Microbiology 37 (2000) 574-582
7. Fourmaux M.N., Achbarou A., Mercereau-Puijalon O., Biderre C., Briche I., Loyens A., Odberg-Ferragut C., Camus D., and Dubremetz J.F. The MIC1 microneme protein of Toxoplasma gondii contains a duplicated receptor-like domain and binds to host cell surface. Molecular and Biochemical Parasitology 83 (1996) 201-210
8. Fox B.A., and Bzik D.J. De novo pyrimidine biosynthesis is required for virulence of Toxoplasma gondii. Nature 415 (2002) 926-929
9. Garcia-Réguet N., Lebrun M., Fourmaux M.N., Mercereau-Puijalon O., Mann T., Beckers C.J., Samyn B., Van Beeumen J., Bout D., and Dubremetz J.F. The microneme protein MIC3 of Toxoplasma gondii is a secretory adhesin that binds to both the surface of the host cells and the surface of the parasite. Cellular Microbiology 2 (2000) 353-364
10. Gravilescu L.C., and Denkers E.Y. IFN-γ overproduction and high level apoptosis are associated with high but not low virulence Toxoplasma gondii infection. Journal of Immunology 167 (2001) 902-909
11. Hitziger N., Dellacasa I., Albiger B., and Barragan A. Dissemination of Toxoplasma gondii to immunoprivileged organs and role of Toll/interleukin-1 receptor signalling for host resistance assessed by in vivo bioluminescence imaging. Cellular Microbiology 7 (2005) 837-848
12. Howe D.K., Summers B.C., and Sibley D. Acute virulence is associated with markers on chromosome VIII in Toxoplasma gondii. Infection and Immunity 64 (1996) 5193-5198
13. Huynh M.H., and Carruthers V.B. Toxoplasma MIC2 is a major determinant of invasion and virulence. PLoS Pathogens 2 (2006) 753-762
14. Ismael A., Sekai D.B., Collin C., Bout D., and Mévélec M.N. The MIC3 gene of Toxoplasma gondii is a novel potent vaccine candidate against toxoplasmosis. Infection and Immunity 71 (2003) 6222-6228
15. Ismael A.B., Dimier-Poisson I., Lebrun M., Dubremetz J.F., Bout D., and Mévélec M.N. Mic1-3knockout of Toxoplasma gondii is a successful vaccine against chronic and congenital toxoplasmosis in mice. Journal of Infectious Disease 194 (2006) 1176-1183
16. Lecomte V., Chumpitazi B.F.F., Pasquier P., Ambroise-Thomas P., and Santoro F. Brain-tissue cyst in rats infected with the RH strain of Toxoplasma gondii. Parasitology Research 78 (1992) 267-269
17. Lee C.W., Sukhumawasi W., and Denkers E. Phosphoinositide-3-kinase-dependant, MyD88-independent induction of CC-type chemokines characterizes the macrophage response to Toxoplasma gondii strains with high virulence. Infection and Immunity 75 (2007) 5788-5797
18. Meissner M., Schlüter D., and Soldati D. Role of Toxoplasma gondii myosin A in powering parasite gliding and host cell invasion. Science 298 (2002) 837-840
19. Mercier C., Howe D.K., Mordue D., Lingbau M., and Sibley L.D. Targeted disruption of the GRA2 locus in Toxoplasma gondii decreases virulence in mice. Infection and Immunity 66 (1998) 4176-4182
20. Mordue D.G., Monroy F., La Regina M., Dinarello C.A., and Sibley L.D. Acute toxoplasmosis leads to lethal overproduction of Th1 cytokines. Journal of Immunology 167 (2001) 4574-4584
21. Nguyen T.D., Bigaignon G., Markine-Goriaynoff D., Heremans H., Nguyen T.N., Warnier G., Delmee M., Warny M., Wolf S.F., Uyttenhove C., Van Snick J., and Coutelier J.P. Virulent Toxoplasma gondii strain RH promotes T-cell-independent overproduction of proinflammatory cytokines IL12 and γ interferon. Journal of Medical Microbiology 52 (2003) 869-876
22. Robben P.M., La Regina M., Kuziel W.A., and Sibley L.D. Recruitment of Gr-1+ monocytes is essential for control of acute toxoplasmosis. Journal of Experimental Medicine 201 (2005) 1761-1769
23. Saeij J.P., Boyle J.P., and Boothroyd J.C. Differences among the three major strains of Toxoplasma gondii and their specific interactions with the infected host. Trends in Parasitology 21 (2005) 476-481
24. Seeber F., and Boothroyd J.C. Escherichia coli β-galactosidase as an in vitro and in vivo reporter enzyme and stable transfection marker in the intracellular protozoan parasite Toxoplasma gondii. Gene 169 (1996) 39-45
25. Su C., Evans D., Cole R.H., Kissinger J.C., Ajioka J.W., and Sibley L.D. Recent expansion of Toxoplasma through enhanced oral transmission. Science 299 (2003) 414-416
26. Taylor S., Barragan A., Su C., Fux B., Fentress F., Tang K., Beatty W.L., El Hajj H., Jerome M., Behnke M.S., White M., Wooton J.C., and Sibley L.D. A secreted serine-threonine kinase determines virulence in the eukaryotic pathogen Toxoplasma gondii. Science 314 (2006) 1776-1780
27. Tenter A.M., Heckeroth A.R., and Weiss L.M. Toxoplasma gondii: from animals to humans. International Journal for Parasitology 30 (2000) 1217-1258
28. Villard O., Candolfi E., Ferguson D.J.P., Marcellin L., and Kien T. Loss of oral infectivity of tissue cysts of Toxoplasma gondii RH strain to outbred Swiss Webster mice. International Journal for Parasitology 27 (1997) 1555-1559
29. Yap G.S., Sharton-Kersten T., Ferguson D.J.P., Howe D.K., Suzuki Y., and Sher A. Partially protective vaccination permits the development of latency in a normally virulent strain of Toxoplasma gondii. Infection and Immunity 66 (1998) 4382-4388
30. Zenner L., Darcy F., Capron A., and Cesbron-Delauw M.F. Toxoplasma gondii: kinetics of the dissemination in the host tissues during the acute phase of infection of mice and rats. Experimental Parasitology 90 (1998) 86-94